Pyrotinib and capecitabine after surgery for HER2+ breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests whether taking pyrotinib (a daily pill) with capecitabine (another pill) after breast cancer surgery can help prevent HER2-positive early-stage breast cancer from coming back. It is for women who have already had their cancer removed and meet certain risk criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old with early-stage, HER2-positive breast cancer that has been surgically removed.
- Your cancer must have either spread to at least one lymph node or be larger than 1 cm (or between 0.5 cm and 1 cm with certain high-risk features).
- You have not been treated before with a type of targeted therapy called a tyrosine kinase inhibitor (like lapatinib, neratinib, or pyrotinib).
- You had your breast cancer surgery (mastectomy or lumpectomy) within the past 90 days.
- Your blood counts, kidney function, and liver function are satisfactory based on recent tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two oral drugs—capecitabine (a chemotherapy pill) and pyrotinib (a targeted therapy)—for people with HER2-positive breast cancer that has spread. It is for those who have already had a recent type of targeted therapy called an ADC and are looking for a new treatment option that does not require a hospital visit.
This trial tests a targeted drug called pyrotinib for women with HER2-positive early or locally advanced breast cancer. It aims to see if adding this treatment before surgery improves outcomes.
This trial tests whether giving a combination of two targeted drugs (pyrotinib and trastuzumab) along with standard chemotherapy before surgery can work better for HER2-positive breast cancer. It is for women whose cancer has not spread to distant organs and who have not yet had treatment for their cancer.
This Phase 2 trial tests pyrotinib, a HER2-targeted cancer medicine, in people with high-risk, HER2-positive breast cancer after surgery. It aims to lower the chance the cancer comes back, especially when standard treatment did not fully clear the tumor.
This trial tests a combination of three drugs—pyrotinib, trastuzumab, and chemotherapy—to treat HER2-positive breast cancer that has not been treated before. HER2 is a protein found on some cancer cells; blocking it may help stop the cancer from growing.
This trial studies whether adding pyrotinib and capecitabine after surgery can lower the risk of cancer coming back in people with very small, lymph-node–negative, HER2-positive breast cancer. It’s for patients who fit specific tumor size and HER2 test results and who can safely take chemotherapy-like medicines and stay on contraception during treatment.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.